Insulet (NASDAQ:PODD – Get Free Report) had its price target boosted by equities researchers at Citigroup from $310.00 to $355.00 in a note issued to investors on Friday,Benzinga reports. The ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...

Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...

CIBC Asset Management Inc increased its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 4.7% in the 4th ...

Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...

Below is a chart showing NOW's trailing twelve month trading history, with the $940 strike highlighted in orange: And Insulet Corp (Symbol: PODD) saw options trading volume of 2,567 contracts ...

Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...